Mounjaro®
Starting from £179.99/mo
Start journey Learn moreBy day two of semaglutide, the medicine is still settling into your system — your first dose is circulating, absorption is ongoing, and most people notice little more than a mild shift in appetite or, for some, the early stirrings of nausea. That is entirely normal. Semaglutide is a prescription-only GLP-1 receptor agonist, licensed in the UK for weight management as Wegovy, and what you experience in the first 48 hours reflects the body adjusting to a starting dose that is deliberately low. A prescriber decides whether this medicine is clinically appropriate for you before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Semaglutide is a once-weekly subcutaneous injection. After you administer the first dose (typically 0.25 mg) the medicine is absorbed slowly through the tissue under the skin and reaches peak plasma concentration at around 24 to 48 hours. That window maps almost exactly onto day two, which is why some people feel a noticeable shift in this period even though the starter dose is intentionally modest.
The GLP-1 receptor agonist mechanism slows gastric emptying (food moves more slowly out of the stomach) and signals to appetite centres in the brain that you are fuller than you might otherwise feel. On day one you may have noticed very little, but by day two those signals are often more perceptible: a meal that would normally feel insufficient leaves you satisfied earlier, or you simply find you are less interested in snacking. Some people experience none of this at all on the first injection and feel it more on the second or third. Both are normal.
The NHS medicines page for semaglutide lists nausea, vomiting, diarrhoea and constipation as the most common side effects, and notes they are typically most pronounced when starting treatment or after a dose increase.
Nausea is the most frequently reported early experience. For most people it is mild (a background queasiness rather than anything incapacitating) and it usually settles within a few days as the body adjusts. Eating smaller portions, choosing blander foods, staying well-hydrated and avoiding rich or fatty meals can all help. The reason fatty food matters is straightforward: gastric emptying is already slowed, so a heavy meal sits in the stomach longer and compounds the discomfort.
Fatigue and a mild headache feature for some people in the first couple of days. Both generally pass without intervention. Constipation or looser stools are also reported, individual responses vary considerably, and neither direction is a cause for alarm in mild form.
There is a misconception worth clearing up gently: some people arrive at day two convinced the nausea means the medicine is working especially well, or that pushing through severe symptoms is virtuous. It is not. Severe, unrelenting nausea, vomiting that prevents you keeping fluids down, or sharp stomach pain that radiates to the back are signals to contact your prescriber or NHS 111 promptly rather than wait. In January 2026 the MHRA issued a Drug Safety Update on GLP-1 medicines specifically highlighting acute pancreatitis (rare but serious) as something clinicians and patients should be alert to. You can report any suspected side effect via the MHRA's Yellow Card scheme.
This is where patience genuinely matters. The 0.25 mg starting dose is not the dose at which meaningful weight loss typically occurs. It exists to help your digestive system acclimatise, to reduce the likelihood of side effects being severe enough to disrupt daily life or lead someone to stop treatment prematurely. Therapeutic benefit builds over months, not days.
In the STEP 1 clinical trial (68 weeks, 2.4 mg maintenance dose), participants lost an average of around 15% of body weight. That outcome is the product of sustained treatment, lifestyle changes alongside the medicine, and gradual dose increases managed by a prescriber. On day two none of that has started yet. The scale on day two is measuring water fluctuations and normal daily variation, not medicine effect.
For a broader look at how semaglutide acts on body fat, or to understand what semaglutide is as a medicine, those pages go into more clinical detail. What day two asks of you is straightforward: rest if you need to, eat lightly, drink water, and let the medicine settle.
Day three often brings a return toward baseline for people who experienced nausea on day two, the peak concentration has passed and the body begins adapting. If you found the first 48 hours easier than expected, that is equally common. A useful reference point is what to expect on day three of semaglutide, which covers the tail of that first-week window.
Your next injection falls seven days after the first. Between now and then, the medicine continues to work at a declining plasma level, but most of the noticeable first-week effects occur in the first three or four days. Staying consistent with injection day and time each week helps keep levels stable and side effects predictable. If you have wondered whether semaglutide works like a stimulant, that page explains why the energy and appetite changes you might notice have a different mechanism entirely.
If you have questions about your experience, the team at our aftercare support is available seven days a week. And if you are still deciding whether semaglutide is the right route for you, the free consultation with our prescribers is the place to start, a real clinician reviews your information the same day, not a piece of software.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.